The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Pharma Innovator Reveals Groundbreaking Diabetes Treatment
Source: Jason Kolbert (01/10/2025)

Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share.

Biotech Advances Breakthrough Cancer Treatment Results
Source: Francois Brisebois (01/10/2025)

Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note.

AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections
Source: Streetwise Reports (01/10/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research.

Should You Double Down on This Story Stock?
Source: Chris Temple (01/07/2025)

Chris Temple of The National Investor explains why he believes you might want to double down on BioLargo Inc. (BLGO:OTCQX).

Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech
Source: Streetwise Reports (01/06/2025)

CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence.